실시간
BioPharma DiveIncyte to buy blood disorder drug in possibly $2B dealFierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse mergerFierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patientsBioPharma DiveJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BEndpoints NewsTreeline to go public via reverse merger with Standard BioToolsBioPharma DiveADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionFierceBiotechResmed snaps up Noctrix Health in $340M sleep tech dealBioWorldBiggest gainers and losers for June 1-5, 2026Endpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldFierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly BioEndpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic optionsEndpoints NewsTango plans Phase 3 pancreatic cancer study after combo success
Endpoints News 2025년 12월 22일

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.